Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine

Claus, Heike; Jördens, Markus S.; Kriz, Pavla; Musílek, Martin; Jarva, Hanna; Pawlik, Marie-Christin; Meri, Seppo; Vogel, Ulrich

doi:10.1016/j.vaccine.2011.11.050

Cited by 12 publications

(14 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the nonrandom association with clonal complexes (16), we found fHbp-1.4, fHbp-3.94, and NHBA-10 to be associated with cnl isolates belonging to cc198, whereas fHbp-2.102 and NHBA-58 were associated with cnl isolates belonging to cc53, as expected from recent studies (60).…”

Section: Discussionsupporting

confidence: 86%

See 1 more Smart Citation

Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years

et al. 2014

View full text Add to dashboard Cite

bNeisseria meningitidis is an obligate human commensal that commonly colonizes the oropharyngeal mucosa. Carriage is age dependent and very common in young adults. The relationships between carriage and invasive disease are not completely understood. In this work, we performed a longitudinal carrier study in adolescents and young adults (173 subjects). Overall, 32 subjects (18.5%) had results that were positive for meningococcal carriage in at least one visit (average monthly carriage rate, 12.1%). Only five subjects tested positive at all four visits. All meningococcal isolates were characterized by molecular and serological techniques. Multilocus sequence typing, PorA typing, and sequencing of the 4CMenB vaccine antigens were used to assess strain diversity. The majority of positive subjects were colonized by capsule null (34.4%) and capsular group B strains (28.1%), accounting for 23.5% and 29.4% of the total number of isolates, respectively. The fHbp and nhba genes were present in all isolates, while the nadA gene was present in 5% of the isolates. The genetic variability of the 4CMenB vaccine antigens in this collection was relatively high compared with that of other disease-causing strain panels. Indications about the persistence of the carriage state were limited to the time span of the study. All strains isolated from the same subject were identical or cumulated minor changes over time. The expression levels and antigenicities of the 4CMenB vaccine antigens in each strain were analyzed by the meningococcal antigen typing system (MATS), which revealed that expression can change over time in the same individual. Future analysis of antigen variability and expression in carrier strains after the introduction of the MenB vaccine will allow for a definition of its impact on nasopharyngeal/oropharyngeal carriage.

show abstract

Section: Discussionsupporting

confidence: 86%

“…On one side, we found isolates genetically unable to express a functional capsule because they were missing the capsule operon (60). These isolates are defined as cnl and are typically found to be associated with harmless meningococcal carriage.…”

Section: Figmentioning

confidence: 99%

Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years

et al. 2014

View full text Add to dashboard Cite

show abstract

“…MATS was also used in two studies [50,51] to evaluate the potential impact of 4CMenB on carriage. In the study of Claus et al [50], 41 strains of capsule null locus meningococci isolated from Germany, Czech Republic and Burkina Faso were analyzed by MATS to predict whether these strains harbor the genes and express the four vaccine antigens of 4CMenB.…”

Section: • • Impact On Carriage Acquisitionmentioning

confidence: 99%

“…In the study of Claus et al [50], 41 strains of capsule null locus meningococci isolated from Germany, Czech Republic and Burkina Faso were analyzed by MATS to predict whether these strains harbor the genes and express the four vaccine antigens of 4CMenB. No strain matched for the PorA subtype 1.4.…”

Section: • • Impact On Carriage Acquisitionmentioning

confidence: 99%

“…Currently, as described above, there is only one clinical trial, with some limitations in its study design, that showed a modest decrease in N. meningitidis carriage in the year following immunization [36]. Moreover two studies that used MATS demonstrated a possible effect of 4CMenB on carriage stage [50,51]. Therefore, the effect of 4CMenB on carriage needs to be further investigated.…”

Section: • • What Is Yet Unknown About 4cmenbmentioning

confidence: 99%

See 1 more Smart Citation

The Multicomponent Meningococcal Serogroup B Vaccine (4CMenB): Origin, Composition, Health Impact and Unknown Aspects

et al. 2015

View full text Add to dashboard Cite

Neisseria meningitidis serogroup B is the main cause for meningococcal invasive disease in many parts of the world. Since 2013, a new multicomponent vaccine against meningococcal serogroup B (4CMenB) has been licensed in Europe, Australia, Canada, Chile, Uruguay, USA and Brazil with different immunization schedules. Clinical trials involving adults, adolescents, children and infants showed 4CMenB has a good immunogenicity and safety profile. Strain coverage estimates are similar to or better than other recently approved vaccines, ranging from 66% in Canada to 91% in Unites States. Some points still remain to be clarified such as the best immunization strategy, the effect of 4CMenB on carriage, the long-term persistence of protective bactericidal antibodies titers, long-term safety outcomes, the possible emergence of N. meningitidis escape mutants and the vaccine cost-effectiveness. In this review, we focus on the vaccine composition, clinical trials and suggested schedules, safety data, potential strain coverage and future challenges.

show abstract

First Synthesis of the α‐L‐Serine Linked Consensus Disaccharide of Neisseria gonorrhoeae and Neisseria meningitidis

Jana

Emmadi

Kulkarni

2015

Israel Journal of Chemistry

View full text Add to dashboard Cite

show abstract

Capsule null locus meningococci: Typing of antigens used in an investigational multicomponent meningococcus serogroup B vaccine

Cited by 12 publications

References 53 publications

Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years

Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years

The Multicomponent Meningococcal Serogroup B Vaccine (4CMenB): Origin, Composition, Health Impact and Unknown Aspects

First Synthesis of the α‐L‐Serine Linked Consensus Disaccharide of Neisseria gonorrhoeae and Neisseria meningitidis

Contact Info

Product

Resources

About